Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
- 18 July 2013
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (1) , 123-128
Abstract
Bortezomib (bort)–dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM). This retrospective study investigated the combination of bort (1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy. The median number of prior lines of therapy was 2. Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort–dex. The median number of bort–dex cycles was 6, up to a maximum of 12 cycles. On an intention-to-treat basis, 55 % of the patients achieved at least partial response, including 19 % CR and 35 % achieved at least very good partial response. Median durations of response, time to next therapy and treatment-free interval were 8, 11.2, and 5.1 months, respectively. The most relevant adverse event was peripheral neuropathy, which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %. With a median follow up of 22 months, median time to progression, progression-free survival (PFS) and overall survival (OS) were 8.9, 8.7, and 22 months, respectively. Prolonged PFS and OS were observed in patients achieving CR and receiving bort–dex a single line of prior therapy. Bort–dex was an effective salvage treatment for MM patients, particularly for those in first relapse.Keywords
This publication has 18 references indexed in Scilit:
- Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short‐livedEuropean Journal of Haematology, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood, 2007
- Proteasome inhibitor bortezomib for the treatment of multiple myelomaLeukemia, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Multiple MyelomaNew England Journal of Medicine, 2004
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998